Danaher (NYSE:DHR) Given New $275.00 Price Target at Barclays

Danaher (NYSE:DHR) had its price target decreased by Barclays from $285.00 to $275.00 in a report issued on Wednesday, Benzinga reports. Barclays currently has an equal weight rating on the conglomerate’s stock.

Other research analysts have also recently issued reports about the stock. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Bank of America raised their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus boosted their target price on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Leerink Partners upped their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird cut their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Price Performance

Shares of DHR stock opened at $256.00 on Wednesday. The company’s 50-day simple moving average is $270.43 and its two-hundred day simple moving average is $260.43. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher has a one year low of $182.09 and a one year high of $281.70. The company has a market capitalization of $189.62 billion, a P/E ratio of 43.39, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 EPS. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, equities analysts anticipate that Danaher will post 7.59 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Danaher by 3.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 79,222 shares of the conglomerate’s stock valued at $21,821,000 after acquiring an additional 2,879 shares during the last quarter. Parcion Private Wealth LLC increased its holdings in Danaher by 5.3% in the 3rd quarter. Parcion Private Wealth LLC now owns 32,261 shares of the conglomerate’s stock valued at $8,969,000 after purchasing an additional 1,615 shares during the last quarter. Allworth Financial LP raised its position in Danaher by 6.1% in the third quarter. Allworth Financial LP now owns 5,337 shares of the conglomerate’s stock valued at $1,484,000 after purchasing an additional 307 shares during the period. Mayfair Advisory Group LLC acquired a new position in Danaher during the third quarter worth $203,000. Finally, Trueblood Wealth Management LLC boosted its position in shares of Danaher by 2.5% during the third quarter. Trueblood Wealth Management LLC now owns 3,382 shares of the conglomerate’s stock worth $940,000 after buying an additional 84 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.